Diversified Portfolios Inc. Buys New Holdings in Eli Lilly and Company (LLY)
Diversified Portfolios Inc. bought a new position in shares of Eli Lilly and Company (NYSE:LLY) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 2,554 shares of the company’s stock, valued at approximately $218,000.
Other large investors have also recently added to or reduced their stakes in the company. Pathstone Family Office LLC grew its holdings in Eli Lilly and by 100.0% during the second quarter. Pathstone Family Office LLC now owns 58 shares of the company’s stock worth $4,774,000 after acquiring an additional 29 shares during the period. Vantage Financial Partners Ltd. Inc. acquired a new position in Eli Lilly and during the second quarter worth about $494,000. Acrospire Investment Management LLC grew its holdings in Eli Lilly and by 16.7% during the second quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock worth $115,000 after acquiring an additional 200 shares during the period. MPS Loria Financial Planners LLC acquired a new position in Eli Lilly and during the second quarter worth about $128,000. Finally, San Francisco Sentry Investment Group CA acquired a new position in Eli Lilly and during the second quarter worth about $129,000. 76.43% of the stock is currently owned by hedge funds and other institutional investors.
In other news, SVP Alfonso G. Zulueta sold 2,003 shares of the firm’s stock in a transaction dated Friday, November 10th. The stock was sold at an average price of $83.67, for a total transaction of $167,591.01. Following the completion of the sale, the senior vice president now directly owns 43,580 shares of the company’s stock, valued at approximately $3,646,338.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Lilly Endowment Inc sold 205,000 shares of the firm’s stock in a transaction dated Wednesday, October 4th. The stock was sold at an average price of $86.81, for a total value of $17,796,050.00. The disclosure for this sale can be found here. Insiders have sold a total of 628,588 shares of company stock valued at $53,399,536 over the last 90 days. Corporate insiders own 0.20% of the company’s stock.
Shares of Eli Lilly and Company (NYSE:LLY) traded up $0.48 during midday trading on Wednesday, reaching $86.06. The company’s stock had a trading volume of 3,876,700 shares, compared to its average volume of 3,672,667. Eli Lilly and Company has a 12-month low of $66.39 and a 12-month high of $89.09. The firm has a market cap of $94,231.72, a price-to-earnings ratio of 20.92, a PEG ratio of 1.88 and a beta of 0.35. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.38 and a quick ratio of 1.03.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, topping the Zacks’ consensus estimate of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The firm had revenue of $5.66 billion during the quarter, compared to analyst estimates of $5.52 billion. During the same period last year, the company posted $0.88 EPS. The business’s quarterly revenue was up 9.0% compared to the same quarter last year. equities research analysts forecast that Eli Lilly and Company will post 4.21 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Wednesday, November 15th will be given a dividend of $0.52 per share. The ex-dividend date of this dividend is Tuesday, November 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.42%. Eli Lilly and’s payout ratio is presently 98.58%.
A number of equities analysts recently weighed in on the company. Morgan Stanley set a $86.00 price target on Eli Lilly and and gave the company a “hold” rating in a research report on Friday, October 6th. Leerink Swann increased their price target on Eli Lilly and from $92.00 to $93.00 and gave the company a “market perform” rating in a research report on Monday, October 23rd. BMO Capital Markets set a $73.00 price target on Eli Lilly and and gave the company a “sell” rating in a research report on Tuesday, October 24th. Credit Suisse Group lowered Eli Lilly and from an “outperform” rating to a “neutral” rating and increased their price target for the company from $84.23 to $88.00 in a research report on Tuesday, October 10th. Finally, Goldman Sachs Group reiterated a “buy” rating and issued a $95.00 price target (up previously from $92.00) on shares of Eli Lilly and in a research report on Thursday, October 5th. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $90.25.
WARNING: “Diversified Portfolios Inc. Buys New Holdings in Eli Lilly and Company (LLY)” was originally posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://theolympiareport.com/2017/12/06/diversified-portfolios-inc-buys-new-holdings-in-eli-lilly-and-company-lly.html.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.